Faricimab, a humanized, bispecific, immunoglobulin G (IgG) monoclonal antibody, has received approval as an intravitreal injection (IVI) from the US Food and Drug Administration for addressing neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion.1,2,3,4,5 This therapeutic molecule is designed to target the vascular endothelial growth factor A (VEGF-A) and the angiopoietin 2 pathways, aiming to enhance vascular stability while mitigating neovascularization and hyperpermeability. This evidence concerns the gene VEGFA and age-related macular degeneration.